HC Wainwright Has Negative Outlook for CBIO FY2025 Earnings

Crescent Biopharma, Inc. (NASDAQ:CBIO) – Analysts at HC Wainwright dropped their FY2025 EPS estimates for Crescent Biopharma in a report released on Monday, November 10th. HC Wainwright analyst M. Kapoor now forecasts that the biopharmaceutical company will post earnings of ($8.80) per share for the year, down from their previous estimate of ($8.43). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Crescent Biopharma’s current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Crescent Biopharma’s Q2 2026 earnings at ($1.35) EPS, Q4 2026 earnings at ($1.41) EPS and FY2026 earnings at ($5.47) EPS.

Crescent Biopharma (NASDAQ:CBIO) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.26). The business had revenue of ($0.75) million for the quarter.

CBIO has been the subject of several other reports. Wall Street Zen upgraded Crescent Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday. Jefferies Financial Group started coverage on Crescent Biopharma in a report on Monday, August 25th. They set a “buy” rating and a $26.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $25.60.

Crescent Biopharma Stock Performance

Shares of CBIO stock opened at $13.25 on Wednesday. The business’s 50 day moving average is $12.46. Crescent Biopharma has a 12-month low of $9.81 and a 12-month high of $44.77. The stock has a market cap of $259.04 million, a price-to-earnings ratio of -0.38 and a beta of 1.50.

Institutional Investors Weigh In On Crescent Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE purchased a new stake in Crescent Biopharma in the second quarter valued at approximately $149,000. Jefferies Financial Group Inc. bought a new position in shares of Crescent Biopharma in the 2nd quarter worth $437,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Crescent Biopharma in the 2nd quarter worth $1,629,000. Braidwell LP purchased a new stake in shares of Crescent Biopharma during the 2nd quarter valued at $4,221,000. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Crescent Biopharma during the 2nd quarter worth $4,520,000. 75.19% of the stock is owned by hedge funds and other institutional investors.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.